Focus: IGC Pharma is a public-stage pharmaceutical company headquartered in Potomac, MD, focused on cannabinoid-based therapeutics for neurology, particularly Alzheimer's disease. The company is early-stage with minimal revenue generation and operates as a clinical-stage biotech.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow IGC Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for IGC Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from IGC Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 - TradingKey
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 TradingKey
The 6 Best Stocks Under 50 Cents To Buy This Year - The Stock Dork
The 6 Best Stocks Under 50 Cents To Buy This Year The Stock Dork
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast - Nonstop Local News
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast Nonstop Local News
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - BioSpace
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts BioSpace
New Strong Buy Stocks for Oct. 24: IGC, ASM and More - MSN
New Strong Buy Stocks for Oct. 24: IGC, ASM and More MSN
The key trends fueling IGC Pharma (IGC) growth potential (Institutional Selling) 2026-05-08 - Wall Street Picks - newser.com
The key trends fueling IGC Pharma (IGC) growth potential (Institutional Selling) 2026-05-08 - Wall Street Picks newser.com
Showing 6 of 10 news items
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo